NCT06300216尚未招募不适用
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Treatment Emergent Adverse Events
研究概览
简要总结
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign an informed consent form and voluntarily participate in this study;
- •Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
- •Age ≥ 18 years old;
- •Treatment with octreotide microspheres.
排除标准
- •Confirmed pregnant or lactating women;
- •Participating in any research with intervention measures outside of routine clinical practice;
- •Other situations unsuitable for inclusion in the study determined by the researcher.
研究组 & 干预措施
Octreotide microspheres standard dose monotherapy
干预措施: Octreotide microspheres (Drug)
结局指标
主要结局
Treatment Emergent Adverse Events
时间窗: up to 46 months
Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With AcromegalyAcromegalyNCT01295060Endo Pharmaceuticals12
终止
1 期
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid SyndromeCarcinoid SyndromeNCT00884715Endo Pharmaceuticals10
招募中
2 期
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06055959UCB Biopharma SRL8
Unknown
2 期
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberGastrointestinal HemorrhageAnemiaHereditary Hemorrhagic TelangiectasiaNCT02874326Radboud University Medical Center15
已完成
3 期
Study of PlasmaCap IG in Adults and Children With PIDDPrimary Immune Deficiency Diseases (PIDD)NCT03238079Evolve Biologics63